4.6.2.4Vertical
Specialty Drug Home Delivery
Companies delivering specialty and biologic medications to patients.
Market snapshot
These figures describe Home Infusion Therapy (4.6.2), the segment that Specialty Drug Home Delivery sits within — not Specialty Drug Home Delivery on its own.
FragmentationConsolidatingEstimate
No discrete Census NAICS code under home health — home infusion spans home health (621610) and pharmacy classifications, so the segment is not separately sized here.
Business model & economics
Revenue model
Drug margin plus nursing and infusion-service fees
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- Drug-margin- and mix-dependent
- Capex intensity
- Moderate
recurring chronic infusion
Characteristics
- Shift of infusion from hospital to home and ambulatory.
- Specialty and biologic drug growth.
- Combines pharmacy, nursing, and logistics.
M&A deal context
Deal activityModerate
Who’s acquiring
- Home-infusion & specialty-pharmacy platforms
- Pharmacy strategics
- PE-backed consolidators
What’s driving deals
- Site-of-care shift to home infusion.
- Specialty-drug growth.
- Consolidation of capability-intensive providers.
Find Specialty Drug Home Delivery acquisition targets
Search Acquisera’s index for companies classified under Specialty Drug Home Delivery (4.6.2.4) and build a targeted deal pipeline.
Search companies